Bile Duct Cancer Market Research Report – Global Forecast Till 2027

Bile Duct Cancer Market Research Report, By Type (Intrahepatic, Extrahepatic), Diagnosis (Blood Tests, Abdominal Imaging, Surgery), By Treatment (Chemotherapy, Radiotherapy), By End User (Hospital& Clinics, Academic Institutes) - Global Forecast till 2027

ID: MRFR/Pharma/3319-HCR | February 2021 | Region: Global | 90 pages

Bile Duct Cancer Market Scenario:


The bile duct cancer market is expected to grow at an approximate CAGR of 9.2% during the forecast period. Bile duct cancer or cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, i.e., they show epithelial differentiation in the bile duct. It is a type of rare neoplasm. According to the National Cancer Institute, in 2014, there were an estimated 66,771 people living with liver and intrahepatic bile duct cancer in the United States. Moreover, the disease is expected to cause 28,920 deaths by the end of 2017 accounting for 4.8% of all cancer deaths.


Rates for new liver and intrahepatic bile duct cancer cases have risen by an average 2.7% each year over the last 10 years. Death rates have been estimated to have risen by an average of 2.6% each year over 2005-2014. Such an increase in the prevalence of bile duct cancer has boosted the market. Additionally, rising healthcare expenditures, increasing awareness for the disease and investments in the R&D for treatment procedures is fuelling the market further. However, high cost of treatment and related side effects along with low healthcare expenditures in the developing economies is expected to restrain the market during the forecasted period.


Segmentation


The bile duct cancer market is segmented on the basis of types, diagnosis, treatment, and end users.


On the basis of types, the market is segmented into intrahepatic, extrahepatic, and others.


On the basis of diagnosis, the market is segmented into blood tests, abdominal imaging, surgery, and others. The diagnosis segment by abdominal imaging is sub segmented into endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), magnetic resonance cholangiopancreatography (MRCP), and others.


On the basis of treatment, the market is segmented into chemotherapyradiotherapy, and others. The chemotherapy segment is sub segmented into 5-fluorouracil, gemcitabine, cisplatin, and others.


On the basis of end users, the market is segmented into hospital &clinics, academic institutes, research organizations and others. 


Figure 1: Global bile duct cancer market share, by Region Bile Duct Cancer Market


Sources: WHO, annual reports, press release, white paper, and company presentation


Regional Analysis


The Americas dominates the bile duct cancer market owing to a well-developed healthcare sector. Apart from this, increasing number of patients, increasing healthcare expenditure have boosted the growth of the market in the Americas. According to the Centers for Disease Control and Prevention, U.S. health care spending in 2015, reached $3.2 trillion or $9,990 per person which accounted for 17.8% of the total GDP.


Europe is the second largest bile duct cancer market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development drives the European market.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge opportunity in the market. According to Indian Brand Equity Fund, the per capita healthcare expenditure in India is estimated to grow at a CAGR of 5% during 2008-15 and reach USD 68.6 by 2015.


On the other hand, the Middle East & Africa has the least share in the bile duct cancer market due to the presence of poor economy especially in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Key players for bile duct cancer market


The key players for the bile duct cancer market are Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Europe), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd. (Middle East), Eli Lilly and Company. (U.S.), Sanofi (Europe), Fresenius Kabi AG (Europe), Mylan N.V. (U.S.), and others. 


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers



Frequently Asked Questions (FAQ) :


Global Bile Duct Cancer Market is expected to exhibit a strong 9.2% CAGR over the forecast period from 2016 to 2023.

The growing awareness about cancer treatments is the major driver for the Bile Duct Cancer Market.

High costs of treatment and unavailability in many emerging countries are the key restraints on Global Bile Duct Cancer Market.

The Americas are the dominant force in the Global Bile Duct Cancer Market.

Leading players in the global bile duct cancer market include Pfizer, Bristol-Myers Squibb, and Eli Lilly, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Bile Duct Cancer Market, by Type

6.1 Introduction

6.2 Intrahepatic

6.2.1 Market Estimates & Forecast, 2020 – 2027

6.3 Extrahepatic

6.3.1 Market Estimates & Forecast, 2020 – 2027

6.4 Others

Chapter 7. Global Bile Duct Cancer Market, by Diagnosis

7.1 Introduction

7.2 Blood Tests

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Abdominal imaging

Market Estimates & Forecast, 2020 – 2027

7.3.1 Endoscopic retrograde cholangiopancreatography (ERCP)

7.3.2 Percutaneous transhepatic cholangiography (PTC)

7.3.3 Magnetic resonance cholangiopancreatography (MRCP)

7.3.4 Others

7.4 Surgery

7.4.1 Market Estimates & Forecast, 2020 – 2027

7.5 Others

7.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter 8. Global Bile Duct Cancer Market, by Treatment

8.1 Introduction

8.2 Chemotherapy

Market Estimates & Forecast, 2020 – 2027

8.2.1 5-fluorouracil

8.2.2 Gemcitabine

8.2.3 Cisplatin

8.2.4 Others

8.3 Radiotherapy

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.4 Others

8.4.1 Market Estimates & Forecast, 2020 – 2027

Chapter 9 Global Bile Duct Cancer Market, by End Users

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2020 – 2027

9.3 Academic Institutes

9.3.1 Market Estimates & Forecast, 2020 – 2027

9.4 Research Organizations

9.4.1 Market Estimates & Forecast, 2020 – 2027

9.5 Others

9.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter 10. Global Bile Duct Cancer Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Pfizer Inc.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 F. Hoffmann-La Roche Ltd

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Bristol-Myers Squibb Company

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Teva Pharmaceutical Industries Ltd.

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Eli Lilly and Company.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Sanofi

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Fresenius Kabi AG

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Mylan N.V.

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of cancer industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Bile Duct Cancer Industry Synopsis, 2020 – 2027

Table 2 Global Bile Duct Cancer Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Bile Duct Cancer Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)

Table 5 Global Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 6 Global Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 8 North America Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)

Table 9 North America Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 10 North America Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 12 US Bile Duct Cancer Market by Type, 2020 – 2027, (USD Million)

Table 13 US Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 US Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 15 US Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 16 Canada Bile Duct Cancer Market by Type, 2020 – 2027, (USD Million)

Table 17 Canada Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 18 Canada Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 20 South America Bile Duct Cancer Market by Type, 2020 – 2027, (USD Million)

Table 21 South America Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 South America Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 24 Europe Bile Duct Cancer Market by Type, 2020 – 2027, (USD Million)

Table 25 Europe Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Europe Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 28 Western Europe Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)

Table 29 Western Europe Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 30 Western Europe Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Market by Type, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

Table 40 Middle East & Africa Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)

Table 41 Middle East & Africa Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 Middle East & Africa Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)

Table 43 Middle East & Africa Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Bile Duct Cancer Market

Figure 3 Segmentation Market Dynamics for Global Bile Duct Cancer Market

Figure 4 Global Bile Duct Cancer Market Share, by Type 2020

Figure 5 Global Bile Duct Cancer Market Share, by Diagnosis 2020

Figure 6 Global Bile Duct Cancer Market Share, by Treatment 2020

Figure 7 Global Bile Duct Cancer Market Share, by End Users, 2020

Figure 8 Global Bile Duct Cancer Market Share, by Region, 2020

Figure 9 North America Bile Duct Cancer Market Share, by Country, 2020

Figure 10 Europe Bile Duct Cancer Market Share, by Country, 2020

Figure 11 Asia Pacific Bile Duct Cancer Market Share, by Country, 2020

Figure 12 Middle East & Africa Bile Duct Cancer Market Share, by Country, 2020

Figure 13 Global Bile Duct Cancer Market: Company Share Analysis, 2020 (%)

Figure 14 Pfizer Inc.: Key Financials

Figure 15 Pfizer Inc.: Segmental Revenue

Figure 16 Pfizer Inc.: Geographical Revenue

Figure 17 F. Hoffmann-La Roche Ltd: Key Financials

Figure 18 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 19 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 20 Bristol-Myers Squibb Company: Key Financials

Figure 21 Bristol-Myers Squibb Company: Segmental Revenue

Figure 22 Bristol-Myers Squibb Company: Geographical Revenue

Figure 23 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 24 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 25 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 26 Sanofi: Key Financials

Figure 27 Sanofi: Segmental Revenue

Figure 28 Sanofi: Geographical Revenue

Figure 29 Fresenius Kabi AG: Key Financials

Figure 30 Fresenius Kabi AG: Segmental Revenue

Figure 31 Fresenius Kabi AG: Geographical Revenue

Figure 32 Mylan N.V.: Key Financials

Figure 33 Mylan N.V.: Segmental Revenue

Figure 34 Mylan N.V.: Geographical Revenue